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Abstract
Cell therapy has been shown to be a key clinical therapeutic option for central nervous system diseases or damage. Stan-
dardization of clinical cell therapy procedures is an important task for professional associations devoted to cell therapy. The
Chinese Branch of the International Association of Neurorestoratology (IANR) completed the first set of guidelines governing
the clinical application of neurorestoration in 2011. The IANR and the Chinese Association of Neurorestoratology (CANR)
collaborated to propose the current version “Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)”.
The IANR council board members and CANR committee members approved this proposal on September 1, 2016, and
recommend it to clinical practitioners of cellular therapy. These guidelines include items of cell type nomenclature, cell quality
control, minimal suggested cell doses, patient-informed consent, indications for undergoing cell therapy, contraindications for
undergoing cell therapy, documentation of procedure and therapy, safety evaluation, efficacy evaluation, policy of repeated
treatments, do not charge patients for unproven therapies, basic principles of cell therapy, and publishing responsibility.
Keywords
cell therapy, neurorestoration, clinical application guideline neurorestoratology
Introduction
The Chinese Branch of the International Association of Neu-
rorestoratology (IANR) established the first guidelines gov-
erning the clinical application of neurorestoration in 2011
(“Chinese Clinical Standard of Neurorestorative Cell
Therapy”)1. These guidelines were revised in 2012 (“Standard
Recommendation for the Application of Chinese Clinical
Cell Therapy For Neurorestoration”)2, in 2015 (“Chinese
Clinical Application Guideline of Neurorestorative Cell
Therapy)3, and in 2016 (“Clinical Cell Therapy Guidelines
for Neurorestoration, China Version 2016”)4. The guideline
and its revisions have played a significant role in standardiz-
ing cell therapy practice in China.
Clinical cell therapies have become increasingly popular
around the world. IANR and the Neurorestoratology Profes-
sional Committee of the Chinese Medical Doctor Association
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(Chinese Association of Neurorestoratology [CANR]) colla-
borated to propose “Clinical Cell Therapy Guidelines
for Neurorestoration (IANR/CANR 2017)” based on the
Chinese version of the guidelines and approved in principle
by the IANR council board members and CANR committee
members on September 1, 2016. The document was subse-
quently edited and literature citations were complemented.
The finalized guidelines were then approved by all IANR/
CANR members by email communication.
IANR/CANR hopes that these guidelines will be accepted
as the applied reference standard for cell therapy of neuro-
logical diseases and damage worldwide. In particular, these
guidelines may be useful to guide researchers who transplant
cells into the brain and spinal cord for therapeutic research
purposes. For the detailed protocol and rules of general cell
therapies, researchers should first follow the regulations and
policies of local governments in their respective countries.
Given the rapidly advancing state of the field, the IANR/
CANR will amend and update the existing guidelines to
reflect the newest results demonstrated in preclinical
research, translational studies, and evidence-based clinical
studies.
Neurorestoratology is an emerging discipline at the inter-
section of clinical medicine and neuroscience. Its goal is to
restore, promote, and maintain the integrity of impaired or
lost neuronal functions and/or structures5.
The “Beijing Declaration of IANR” (agreed upon at the
IANR 2015 Conference in Tehran) declared as its fundamen-
tal tenet that “functional recovery is possible after central
nervous system (CNS) injury and neurodegeneration” and
noted that “cell therapies may become a key clinical thera-
peutic option for acute, subacute and/or chronic CNS dis-
eases or damage”5. More than 30 types of cells have been
identified through preclinical studies as having the capacity
for neurorestoration6–66.
The US Food and Drug Administration (Guidance for
Industry: Preclinical Assessment of Investigational Cellu-
lar and Gene Therapy Products) divided cell therapy prod-
ucts into stem cell–derived cell therapy products and
mature/functionally differentiated cell-derived cell therapy
products (http://www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guidances/
default.htm). Stem cell–derived cell therapy products
include embryonic stem cells (ESCs), induced pluripotent
stem cells, and adult (multipotent) stem cells. The last one
contains neural stem cells (NSCs) and mesenchymal stem
cells of different types. Mature/functionally differentiated
cell-derived cell therapy products include (1) specialized
functional cells such as neural progenitor or precursor cells,
olfactory ensheathing cells (OECs), Schwann precursor
cells, oligodendroglia precursors, neural-restricted precur-
sors, glial-restricted precursors, neutrophils, neurons, astro-
cytes, myoblasts, and so on; and (2) nonspecialized
functional cells such as bone marrow or umbilical cord
blood mononuclear cells, umbilical cord or adipose stromal
cells, and fibroblasts and lymphocytes63,64,67–71. Even
though there is some disagreement or controversy concern-
ing the nomenclature of MSCs, so far the majority has
accepted the MSC standard criteria made by the Interna-
tional Society for Cellular Therapy to identify MSCs72,73.
While MSCs containing mesenchymal stem cells are able
to differentiate into other (adipocytes, chondrocytes, osteo-
cytes, etc.) kinds of cells when cultured in special media for
differentiation, this kind of study can be referred to as
mesenchymal stem cell research. In those cases, MSCs are
cultured for expansion without differentiation; we may
refer to this type of study as MSC research. Currently, there
remains some misuse of these MSC standard criteria to
identify their culturing and expanding MSCs and call them
mesenchymal stem cells.
Due to concerns over tumorigenicity and difficulties in
controlling differentiation of pluripotent or multipotent stem
cells, stem cell–derived cell therapy products require more
extensive preclinical and clinical testing. The clinical guide-
lines presented in this document apply more to mature/
functionally differentiated cell therapy. To date, clinical
trials of treatments based on those categories of cells have
been carried out in over 40 countries with documented safety
and functional neurological improvement for patients with
CNS diseases and damage74–114.
Recommended Standards for Personnel
and Institutions Conducting Cell Therapies
Equipment
Institutions applying cell therapies to patients must have
certified laboratory facilities and equipment that comply
with the relevant national standards for ensuring cell quality
control (Fig. 1).
Personnel
Clinical personnel. Physicians performing cell transplantation
procedures should have documented professional training
and certification required to ensure high-level competency
in this field. They should have passed all certification exam-
inations recommended by the relevant professional societies
or associations.
Laboratory personnel. Directors of cell preparation labora-
tories should have achieved a high professional rank. Tech-
nicians involved in cell preparation should have undergone
all relevant professional training and passed all certification
examinations in cell preparation recommended by the rele-
vant professional societies or associations.
Oversight personnel. Inspectors assessing cell quality should
have undergone all relevant professional training and passed
all certification examinations in cell preparation recom-
mended by the relevant professional societies or associations
(Fig. 1).
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Institutional Review Board and Ethics
Committee Approval
All clinical studies or treatment involving cell therapies and
human participants must be reviewed and approved by the
appropriate institutional review board or ethics committee
(Fig. 1).
Provisions
These guidelines include the following provisions: cell type
nomenclature, cell quality control, minimal suggested cell
doses, patient informed consent, indications for undergoing
cell therapy, contraindications for undergoing cell therapy,
documentation of procedure and therapy, safety evaluation,
efficacy evaluation, policy of repeated treatments, do not
charge patients for unproven therapies, basic principles of
cell therapy, and publishing responsibility (Fig. 2).
Cell Type Nomenclature
Cells are the basic unit of structure and function of organ-
isms. A stem cell can generate itself in a process known as
self-renewal and also produce the other kinds of more differ-
entiated, committed cells with specialized functions. Pro-
genitor or precursor cells are not able to self-renew but
instead can multiply rapidly and differentiate into one or
more kinds of specialized cells. Mature and functionally
differentiated cells usually cannot make additional cells
unless they dedifferentiate.
The nomenclature and description of cells used for ther-
apy should specify developmental stage (e.g., embryonic,
fetal, neonatal, adult, allogeneic, and autologous), tissue of
origin (e.g., blood, bone marrow, umbilical cord blood, pla-
centa, brain, spinal cord, olfactory bulb, subventricular zone,
peripheral nerve, adipose, tumor, and cell line), method to
isolate or expand the cells (e.g., genetically induced,
expanded in culture, laser sorted, minimally manipulated,
centrifugation, and type of osmotic gradient), and selection
process (e.g., human leukocyte antigen [HLA]- or ABO
blood group-matched, CD34þ, and aldehyde dehydrogenase
expressing). If nonhuman, the species must be specified. If
mixtures of cells are used, the type of cells should be spec-
ified (e.g., mononuclear) together with the approximate per-
centages of the different types of cells present in the mixture
(Fig. 3).
Cell Quality Control
Quality control is essential for ensuring safety and efficacy
of cell therapies. Quality control encompasses cell collec-
tion; culturing; identifying; amplifying; detecting composi-
tion and relevant cytokines, genetic or other manipulations,
and passage number; exogenous factors; cell storage;
assessment of biological effects (dynamics proliferation);
cell transportation; preparation before clinical use; surgery
and cell transplantation; or other administrative approaches.
Use of animal serum such as fetal bovine serum (FBS) is
discouraged. If FBS is used, it should be washed
or otherwise removed before transplantation. If human
sera are used, the source and quality of the serum must
be documented.
Sterility of the cell preparation must be rigorously mon-
itored. Because microbiological cultures may take days or
even weeks to complete, the sterility of the cell preparation
procedure must be carefully assessed and validated,
Cell
• Cell type nomenclature
• Cell quality control
• Minimal suggested cell doses
• Patient informed consent
• Indications for undergoing cell therapy
• Contraindications for undergoing cell therapy
Patient 
• Safety evaluation
• Efficacy evaluation
• Policy of repeated treatments
• No charge to patients for unproven therapies
• Basic principle of cell therapy
• Publishing responsibility.
Evaluation
Other
Fig. 2. Provisions for cell therapy.
• Certified laboratory 
facilities and equipment
• Cell quality control 
1. Institution 2. Personnel 3. Ethic
• Clinical personnel
• Laboratory personnel
• Oversight personnel
• Institutional review 
board and ethics 
committee approval
Fig. 1. Recommended standards for personnel and institutions.
The standards mainly contain 3 parts: equipment, personal and
institutional review board, and ethics committee approval.
Developmental stage
Tissue of origin
Isolation methods
Selection process
Type of cells
Mixed cells
Single cell
Expansion methods
Non-Human human
Fig. 3. Provision for cell type nomenclature. The nomenclature and
description of the cells used for therapy should specify species,
developmental stage, tissue of origin, method to isolate or expand
the cells, and selection process. If mixtures of cells are used, the
type of cells should be specified.
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particularly if the cells are transplanted before sterility data
are available. If sterility testing reveals that the cells are
contaminated with bacteria, fungus, or virus, sensitivity to
antibiotics, antivirals, or fungicides should be determined. If
the cells come from donor sources where infections are pos-
sible, donors should be screened for human immunodefi-
ciency virus, hepatitis B virus, cytomegalovirus, or other
prevalent contaminants. In addition, if tissues are stored at
room temperature for any length of time, endotoxin levels
should be determined. Before cells are frozen and stored,
dimethylsulfoxide should be tested. The standards for steri-
lity depend on the type and source of cells and route of
administration. For example, administration of cells to skin
or eyes may require criteria as stringent as for their admin-
istration to the CNS.
Before transplantation, certain minimal information must
be obtained concerning the cells. These include the number
of nucleated cells, the number or percentage of therapeuti-
cally relevant cells, and cell viability. Some information may
be obtained after treatment as long as the preparation process
is validated and contaminants can be treated with antibiotics,
antivirals, or fungicides. The maximum time between pre-
paration and transplantation of cells should be based on evi-
dence115 (Fig. 4).
Minimal Suggested Cell Doses
Cells must be used at an effective dose. Thus, the cell dosage
and injection volume must be determined and controlled
based on evidence of efficacy and safety. Currently, we rec-
ommend that the maximum injection volume of cell suspen-
sions does not exceed 200 mL per injection for brain
parenchyma79,116–118, 25 mL per injection into spinal cord
parenchyma74,75, 10 mL by intrathecal injection into cere-
brospinal fluid119,120, and 10 to 100 mL by intravenous and
intra-arterial routes120–124. The volume or number of cells
being transplanted will be reformulated if further trials show
stronger evidence or indicate suitable doses in terms of
patient body weight.
Current recommendations for a commonly used single
dose of cells are as follows (Table 1):
(1) OECs and Schwann cells: 2 to 3  106 cells for
intrathecal injection, 1 to 2  106 cells for
intraspinal spinal cord injection, and 2 to 4 
106 cells for brain parenchymal
injection74,75,79,118,125.
(2) Neural progenitor/ precursor cells: 5 to 6 106 cells
by intrathecal injection, 5 to 6  106 cells for spinal
• Cell transportation
• Preparation before clinical use
• Surgery and cell transplantation 
• Other administrative approaches
• Collection and culture
• Identification and amplification
• Cell storage
• Assessment of biological effects
• Sterility testing 
• Passage number
• Genetic or other manipulations
• Composition and relevant cytokines
Cells
Detection
Administration
Quality control
Fig. 4. Cell quality control. Quality control is essential for ensuring safety and efficacy of cell therapies from the preparation of cells to cell
transplantation. Sterility of the cell preparation must be rigorously monitored.
Table 1. Minimal Suggested Cell Doses.
Olfactory ensheathing cells and Schwann cells 2–3  106 1–2  106 2–4  106 —
Neural progenitor/precursor cells 5–6  106 5–6  106 10  106
(or lateral ventricle)
—
Mesenchymal stromal cells derived from umbilical cord 5–8  106 — 10  106 0.5–0.8  106/kg
Mononuclear cells derived from cord blood 5–6  106 6–7  106 (above and
below the injury site)
— 1–2  106/kg
Mononuclear cells derived from bone marrow 5–6  106 — — 3–9  108
Note. Current recommendations of commonly used single dose of different cells, including olfactory ensheathing cells and Schwann cells, neural progenitor/
precursor cells, mesenchymal stromal cells derived from umbilical cord, mononuclear cells derived from cord blood, and mononuclear cells derived from
bone marrow.
314 Cell Transplantation 27(2)
cord injection, and 10  106 by brain parenchymal
injection118,123,125 or lateral ventricle126.
(3) MSCs derived from umbilical cord: 0.5 to 0.8 
106/kg body weight for intravenous infusion (the
dose should be reduced by 1/3 to 1/2 for elderly and
frail patients), 5 to 8  106 for intrathecal injection,
and 10 106 for brain parenchymal injection127–134.
(4) Mononuclear cells derived from cord blood: 1 to 2 
106/kg body weight by intravenous infusion (the dose
should be reduced by 1/3 to 1/2 for elderly and frail
patients), 5 to 6  106 by intrathecal injec-
tion81,87,90,94, and a total of 6 to 7 106 cells injected
into spinal cord above and below the injury site135.
(5) Mononuclear cells derived from bone marrow: 3 to
9  108 by intravenous infusion and 5 to 6  106 by
intrathecal injection84,86,121,122,124,126.
Patient-Informed Consent
Two types of informed consent must be obtained. The first is
from donors or parents who must give consent for the cells to
be used to treat other patients. For example, if cells are
obtained from aborted fetuses, the parent must understand
what the cells will be used for and give informed consent. The
second is informed consent of the recipient of the cells.
Patients and their families have the right to know all the pos-
sible benefits and potential risks of matters related with the cell
transplantation and procedures. Physicians should continue to
learn and master the latest cell therapy–related knowledge in
order to give objective answers and explanations. All partici-
pants must complete and sign a consent form that is approved
by the appropriate institutional review board or ethical com-
mittee before the clinical study or cell therapy is applied.
Indications for Undergoing Cell Therapy
Animal studies suggest that cell therapies may be beneficial
for a variety of neurological diseases and injury including
neurotraumatic injury, neurodegeneration, ischemic/hypoxic
brain injury, demyelination, sensory motor disorders, neuro-
pathic pain, and nerve damage caused by intoxication, phys-
ical/chemical factors, immune and infectious, inflammatory,
hereditary, congenital or developmental factors, and so on.
However, until formal regulatory approval is obtained for
use of cell therapies for specific indications, cell therapy
must be administered only under the auspices of clinical
trials and studies approved by appropriate institutional
review boards, ethical committees, and regulatory agencies.
The relevant committees for each type of neurorestorative
treatment should document the special indications for each
treatment and the disease categories.
Contraindications for Undergoing Cell Therapy
Patients with poor health or dysfunction of major organs may
not tolerate surgery or cell therapy procedures. The presence
of infections, pressure sores, bleeding tendency, coagulation
disorders, and emotional disturbance likewise may introduce
undesirable complications. Patients with active neoplastic
diseases, hypersensitivity, or pregnancy likewise should be
excluded unless the cell therapy is specifically intended for
these conditions. Clinicians should consider the likelihood
that a high incidence of complications risks creating unne-
cessarily negative and undesirable issues for cell therapy or
transplantation procedures.
Documentation of the Procedure and Therapy
The operative procedures, cell therapy, and outcomes must
be rigorously documented. The documented data include
anesthesia methods, cell quality and source, surgical proce-
dures, transplantation method and site, cell preparation and
dose, treatment timing at different stages, and both short-
and long-term outcomes.
More preclinical and clinical treatment studies are needed
to establish the best doses and therapeutic routes for different
cell therapies and conditions. Randomized double-blind
clinical trials are needed to establish and validate the safest
and most effective clinical practices74,75,79,118,128–130,136–139.
Specific sites of transplantation should be compared and
assessed. For example, in local brain disorders (trauma or
stroke), should the cells be injected into the lesion edge? For
nonspecial or diffuse disorders (cerebral palsy, amyotrophic
lateral sclerosis), what is the best site to inject cells? Should
they be injected into the key points for neural network
restoration75,79? Some experience suggests that these key
points are located anterior to the lateral ventricle and 23 to
27 mm from the midline, where the frontal corona radiata
and pyramidal tract pass through and represent a nexus
where numerous projection fibers, association fibers, and
commissural fibers converge. Where is the best place to
inject into the spinal cord? Some data suggest that cells
should be injected into the spinal cord below and above the
injury site, at the junction of normal and damaged tissue. For
peripheral nerve disorders, should the cells be injected into
the damaged site? For brain or spinal cord injury, when is the
optimal time window for cell therapy, which mode of cell
transplantation is better and what kind of cells should be
selected at different stages? All these questions need to be
answered in future clinical studies.
Safety Evaluation
Detailed records must be kept for cell therapy–related
adverse events by using standardized terminology such as
fever, headache, nausea, vomiting, anorexia, infection, rash,
poor wound healing, dyspnea, increased/decreased blood
pressure, increased/decreased heart rate, neurological dete-
rioration, cerebrospinal fluid leakage, twitch, and so on. In
the case of mortality, autopsies should be carried out to
determine the cause of death and disposition of the trans-
planted cells.
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Efficacy Evaluation
Efficacy of cell therapies should be evaluated by validated
and established standards or scales currently used in the
international community to assess the patients’ functions for
different diseases (referred to as neurorestoratology138 or
CNS neurorestoratology139). Many organizations, including
IANR, regularly hold training courses for physicians to learn
specific standards and assessments of patients, to test and
evaluate proficiency and consistency, such as volitional con-
trol which is evaluated by a motor task involving single and
multijoint movement performed repetitively at the same rate
and amplitude and provide professional certification. Inde-
pendent third-party examiners are recommended for clinical
trials. Randomized double-blind controlled trials are pre-
ferred and required for regulatory approval. Whenever pos-
sible, detailed imaging information should be obtained
before and after therapy, including magnetic resonance ima-
ging (MRI) scans, such as functional MRI, and diffusion
tensor MRI and electrophysiological examination such as
transcranial magnetic stimulation (TMS), evoked potential
(EP), and electromyogram (EMG) to document the presence
of the cells or therapeutic effects. Patients should be sched-
uled for long-term follow-up examinations to determine
whether beneficial effects are lasting. Functional and
quality-of-life scales should be used to assess the impact of
treatment effects. Natural recovery can occur over a period of
time before it stops. This time may differ in different patho-
logical conditions. It is therefore important to record the time
elapsed between the pathological event and the intervention
and to document other previous treatments (surgical, medical,
or pharmacological) and the time prior to the cellular
intervention.
Policy of Repeated Treatments
Repeated cell therapies should be based on convincing evi-
dence of efficacy. In the absence of such evidence, patients
should not be told that repeated transplants are more effec-
tive. If such evidence is not available, clinicians should do
randomized trials to obtain such evidence. For example, one
possible approach is to use a randomized crossover trial
design, where patients are randomized to early or late
repeated therapy. To rule out potential placebo effects, some
trials should involve sham transplant procedures.
Do Not Charge Patients for Unproven Therapies
There should be agreement within the treatment community
that if clinical trials do not show convincing evidence of
benefit, practice of the therapy should be discontinued.
Patients should not pay for experimental therapies. While
there may be differing standards for proof of safety and
efficacy, charging patients for unproven cell therapies with-
out regulatory approval is not only illegal but may give cell
therapy a bad reputation with regulatory agencies and delay
acceptance of cell therapy by the mainstream clinical com-
munity. Approved medical treatments including cell thera-
pies will not be fit for this agreement. Many countries and
areas such as the United States, India, and Europe140, how-
ever, are adopting the practice of allowing compassionate
use of therapies shown to be safe and with some evidence
of efficacy to treat disorders for which there is no known
effective therapy. Regulatory agencies will often negotiate
with the clinician or company for the patient to pay the cost
of the therapy.
Basic Principles of Cell Therapy
A number of clinical studies concerning cell therapies with a
positive outcome have led to the suggestion that combination
cell therapies and/or certain transplantation approaches with
rehabilitation can be more effective107,123,128–130,136,138–200.
IANR/CANR will evaluate such data and actively organize
multicenter studies to test these practices for different cells
and diseases. Randomized, double-blind, and controlled
clinical studies should be carried out, if at all possible.
Publishing Responsibility
All groups that practice clinical cell therapies must promptly
analyze and publish their data in peer-reviewed journals, so
that other physicians can have access to the information.
Summary. Clinical cell therapies for neurological diseases and
damage have shown promise for functional neurorestoration.
These guidelines will help to promote the development of
clinical cell therapies. Although currently multiple cell types
have being used or have continued use for neurorestora-
tion201,202, additional studies are necessary to determine the
best type, doses, route, and timing window for administration.
Further investigations in human patients will enhance our
comprehension of this up-and-coming treatment.
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